Formula (I) And formula (VI) At the compound represented by the stroke intimal thickening cancer angiogenesis, rheumatoid arthritis, of percutaneous vascular coronary angioplasty, vascular atherosclerosis, hemorrhagic type because it has a MMP-9 production inhibitory action therapeutic agents as well as preventive medicine acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial lung fibrosis, chronic sinusitis, bronchitis, chronic obstructive pulmonary disease to (COPD) as, it is useful as a drug with less side effects than the MMP enzyme activity inhibitor of conventional.式(I)及び式(VI)で示される化合物はMMP-9産生抑制作用を有するため癌性血管新生、慢性関節リウマチ、経皮的経血管的冠動脈形成術後の血管内膜肥厚、血管粥状硬化症、出血性型の脳卒中、急性心筋梗塞、慢性心不全、動脈瘤、肺癌転移、成人呼吸窮迫症候群、喘息、間質性肺線維症、慢性副鼻腔炎、気管支炎、慢性閉塞性肺疾患(COPD)に対する予防薬ならびに治療薬として、従来のMMP酵素活性阻害剤よりも副作用の少ない薬剤として有用である。
